Cochrane · systematic review · CD007733
Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS)
Afshari, A, Bastholm Bille, A, Allingstrup, M · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
3
No studies
1
Included studies
NR
No studies 1 · 25%Ungraded 0 · 0%Very low 3 · 75%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyAerosolized prostacyclin compared to placebo for acute respiratory distress syndrome (ARDS)
Population: people with ARDS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Aerosolized prostacyclin vs placebo | RR 1.5 [0.17, 12.94] | 1 study · 14 participants | Very low |
PaO2/FiO2 ratio5 Aerosolized prostacyclin vs placebo | no estimate extracted | 1 study · 67 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Improvement in mean pulmonary arterial pressure Aerosolized prostacyclin vs placebo | no estimate extracted | NR | No studies |
Adverse events7 Aerosolized prostacyclin vs placebo | no estimate extracted | 2 studies · 81 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Mortality for patients with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)
Population: patients with Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
days mortality, paediatric, low bias trial | RR 1.5 [0.17, 12.94] | 1 study · 14 participants | Low Downgraded: inconsistency |